Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants
Status:
Completed
Trial end date:
2020-05-28
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind (sponsor-open), placebo-controlled, single-center study
involving Japanese participants. The purpose of the study is to assess the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity after a single
subcutaneous (SC) dose of GSK2330811 in healthy Japanese participants. GSK2330811 is a
humanized immunoglobulin G1 (IgG1) monoclonal antibody that binds and inhibits the action of
Oncostatin M (OSM) and is being developed for the treatment of Crohn's disease (CD) and
Systemic sclerosis (SSc). Participants will be randomized to receive either GSK2330811 (450
milligram [mg]) or placebo in an approximate ratio of 7:3.